Triple-Drug cocktail targets Hard-to-Treat colorectal cancer
NCT ID NCT06784947
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (tiragolumab, atezolizumab, and bevacizumab) in people with a type of advanced colorectal cancer that has not responded to prior treatments. The goal is to see if the combo can shrink tumors or slow the disease. Participants receive the drugs and are monitored with scans and lab tests. The study is small (13 people) and in phase 2, so results will show if this approach is promising enough for larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universtiy of Colorado Hospital
Aurora, Colorado, 80045, United States